InMed Pharmaceuticals GAAP EPS of -$0.44

* InMed Pharmaceuticals press release [https://seekingalpha.com/pr/20298167-inmed-reports-first-quarter-fiscal-2026-financial-results-and-provides-business-update] (INM [https://seekingalpha.com/symbol/INM]): Q1 GAAP EPS of -$0.44.
* As of September 30, 2025, the Company's cash and cash equivalents were $9.3 million, which compares to $11.1 million on June 30, 2025. The Company continues to closely monitor expenses while advancing its pharmaceutical pipeline candidates. Based on current forecasts, the Company expects its cash will be sufficient to fund its planned operating expenses and capital expenditure into the fourth quarter of calendar year 2026, depending on the level and timing of BayMedica commercial revenues, as well as the level and timing of our operating expenses.

MORE ON INMED PHARMACEUTICALS

* Seeking Alpha’s Quant Rating on InMed Pharmaceuticals [https://seekingalpha.com/symbol/INM/ratings/quant-ratings]
* Financial information for InMed Pharmaceuticals [https://seekingalpha.com/symbol/INM/income-statement]